Rubix LS, founded in 2016 and based in Lawrence, Mass., builds data, products, processes, and programs to incorporate minority data sets across every phase of the life‑science development ecosystem. Its core product is StarSense, a virtual clinical trial platform designed to enhance minority patient recruitment, engagement, support, and education. StarSense advanced globally during the COVID-19 pandemic to support underrepresented groups in infectious disease clinical trial programs and, per the company, has led to a 38% increase in therapeutic benefits for therapies previously unknown to support certain conditions. The firm emphasizes culturally‑centric solutions to build trust and ensure underrepresented communities can access therapies and continued care. Financially, Rubix LS completed a $1.25 million Seed financing and reports a rapidly growing roster of clients, expansion of its internal team, and strong market momentum in addressing health inequities.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2021